| full name | Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men |
|---|---|
| other names | CT02720094 |
| sponsor | ViiV Healthcare, Gilead Sciences[1] |
| number of participants | 4500[1] |
| start | 20 December 2016[2] |
| primary completion | June 2020[1] |
HPTN 083 is a 2016 clinical trial which compares cabotegravir injections with oral use of Emtricitabine/tenofovir as pre-exposure prophylaxis ("PrEP") for prevention of HIV/AIDS.
The study seeks to test injectable PrEP as a way to remedy adherence for many patients on a daily pill regimen.[3]
HPTN 083 is the first large scale phase III clinical trial of cabotegravir.[4]
In February 2016 researchers presented the results of the ECLAIR study.[5] That study examined cabotegravir and found no serious safety concerns.[5]
The research is a collaboration of Gilead Sciences, HIV Prevention Trials Network, ViiV Healthcare, National Institute of Allergy and Infectious Diseases.[6]
Local study sites will include John H. Stroger Jr. Hospital of Cook County.[7]
On May 18, 2020, HPTN announced that the long-acting injections had been found to be a highly effective treatment.[8]
References[edit]
- ^ a b c "Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men". clinicaltrials.gov. 3 February 2017. Retrieved 6 February 2017.
- ^ "NIH Launches First Large Trial of a Long-Acting Injectable Drug for HIV Prevention | NIH: National Institute of Allergy and Infectious Diseases". www.niaid.nih.gov. 20 December 2016. Retrieved 6 February 2017.
- ^ Surugue, Léa (28 December 2016). "New PrEP drug could be a 'game-changer' to protect people from HIV infection". International Business Times UK. Retrieved 6 February 2017.
- ^ Rosa, Kristi (22 December 2016). "Will Cabotegravir be a Game-changer in HIV Prevention?". ContagionLive. Retrieved 6 February 2017.
- ^ a b Cairns, Gus (11 November 2016). "The 'long tail' problem: injected-PrEP trial will be extended due to persistence of drug in companion study". Aidsmap. Retrieved 6 February 2017.
- ^ "Viiv HealthCare initiates Phase III HPTN 083 study of cabotegravir versus Truvadafor Pre-Exposure Prophylaxis (PrEP)to prevent HIV infection., 22-Dec-16". Medthority.com. 22 December 2016. Retrieved 6 February 2017.
- ^ Thomas, Monifa (9 January 2017). "CCHHS Part of First Study to Test Efficacy and Safety Of A New HIV-Prevention Medication". Daily Southtown. Retrieved 6 February 2017.
- ^ "Long-acting injectable cabotegravir is highly effective for the prevention of HIV infection in cisgender men and transgender women who have sex with men | The HIV Prevention Trials Network". www.hptn.org. Retrieved 2020-05-18.
External links[edit]
- official page at ClinicalTrials.gov
- HPTN 083: The HIV Life Cycle With Cabotegravir, a video provided by HPTN
Well, that’s interesting to know that Psilotum nudum are known as whisk ferns. Psilotum nudum is the commoner species of the two. While the P. flaccidum is a rare species and is found in the tropical islands. Both the species are usually epiphytic in habit and grow upon tree ferns. These species may also be terrestrial and grow in humus or in the crevices of the rocks.
View the detailed Guide of Psilotum nudum: Detailed Study Of Psilotum Nudum (Whisk Fern), Classification, Anatomy, Reproduction